Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial

OBJECTIVE: To evaluate the efficacy and safety of ustekinumab through 2 years in adult patients with active psoriatic arthritis (PsA). METHODS: A total of 615 adult patients with active PsA were randomized to placebo, ustekinumab 45 mg, or ustekinumab 90 mg, at weeks 0, 4, and every 12 weeks through...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanaugh, Arthur, Puig, Lluís, Gottlieb, Alice B., Ritchlin, Christopher, Li, Shu, Wang, Yuhua, Mendelsohn, Alan M., Song, Michael, Zhu, Yaowei, Rahman, Proton, McInnes, Iain B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063124/
https://www.ncbi.nlm.nih.gov/pubmed/26097039
http://dx.doi.org/10.1002/acr.22645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063124/
https://www.ncbi.nlm.nih.gov/pubmed/26097039
http://dx.doi.org/10.1002/acr.22645

Ejemplares similares